FAP Radioligand Linker Optimization Improves Tumor Dose and Tumor-to-Healthy Organ Ratios in 4T1 Syngeneic Model
Journal of Medicinal Chemistry · 25.07.2024 · 67 (14) · 11827-11840
DOI: 10.1021/acs.jmedchem.4c00448 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 16.07.2024. Verfasst von Spencer D Lindeman und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Institute for Drug Discovery, Purdue University, West Lafayette, Indiana 47907, United States. Hauptthemen laut MEDLINE: Endopeptidases, Mice, Inbred BALB C, Membrane Proteins, Radiopharmaceuticals. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 102 Literaturangaben. Gefördert von: Purdue University, MorphImmune, Inc..
Abstract (Originalsprache)
Fibroblast activation protein (FAP) has attracted considerable attention as a possible target for the radiotherapy of solid tumors. Unfortunately, initial efforts to treat solid tumors with FAP-targeted radionuclides have yielded only modest clinical responses, suggesting that further improvements in the molecular design of FAP-targeted radiopharmaceutical therapies (RPT) are warranted. In this study, we report several advances on the previously described FAP6 radioligand that increase tumor retention and accelerate healthy tissue clearance. Seven FAP6 derivatives with different linkers or albumin binders were synthesized, radiolabeled, and investigated for their effects on binding and cellular uptake. The radioligands were then characterized in 4T1 tumor-bearing Balb/c mice using both single-photon emission computed tomography (SPECT) and ex vivo biodistribution analyses to identify the conjugate with the best tumor retention and tumor-to-healthy organ ratios. The results reveal an optimized FAP6 radioligand that exhibits efficacy and safety properties that potentially justify its translation into the clinic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Institute for Drug Discovery, Purdue University, West Lafayette, Indiana 47907, United States.
- MorphImmune, Inc., 1281 Win Hentschel Blvd, West Lafayette, Indiana 47906, United States.
ORCID-Profile: Spencer D Lindeman, Owen C Booth, Jackson N Moss, Ramesh Mukkamala, Lauren K Thompson, Madduri Srinivasarao
Förderung
- Purdue University
- MorphImmune, Inc.
Zitieren
APA
Lindeman, S. D., Booth, O. C., Tudi, P., Schleinkofer, T. C., Moss, J. N., Kearney, N. B., Mukkamala, R., Thompson, L. K., Modany, M. A., Srinivasarao, M., & Low, P. S. (2024). FAP Radioligand Linker Optimization Improves Tumor Dose and Tumor-to-Healthy Organ Ratios in 4T1 Syngeneic Model. Journal of Medicinal Chemistry, 67(14), 11827-11840. https://doi.org/10.1021/acs.jmedchem.4c00448
Vancouver
Lindeman SD, Booth OC, Tudi P, Schleinkofer TC, Moss JN, Kearney NB, et al. FAP Radioligand Linker Optimization Improves Tumor Dose and Tumor-to-Healthy Organ Ratios in 4T1 Syngeneic Model. Journal of Medicinal Chemistry. 2024;67(14):11827-11840. doi:10.1021/acs.jmedchem.4c00448
BibTeX
@article{Lindeman2024,
author = {Lindeman, Spencer D and Booth, Owen C and Tudi, Pooja and Schleinkofer, Taylor C and Moss, Jackson N and Kearney, Nicholas B and Mukkamala, Ramesh and Thompson, Lauren K and Modany, Mollie A and Srinivasarao, Madduri and Low, Philip S},
title = {FAP Radioligand Linker Optimization Improves Tumor Dose and Tumor-to-Healthy Organ Ratios in 4T1 Syngeneic Model},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {14},
pages = {11827--11840},
doi = {10.1021/acs.jmedchem.4c00448}
}
EUVIMED